Table 2.
Clinicopathological characteristics of the two groups.
| Clinicopathological characteristics | Recurrent and metastatic group (n = 131) | Control group (n = 121) | Total | χ 2 | p |
|---|---|---|---|---|---|
| Pathological type, n (%) | |||||
| Invasive carcinoma | 115 (87.78%) | 102 (84.30%) | 217 (86.11%) | 4.349 | 0.114 |
| Intraductal carcinoma | 2 (1.53%) | 8 (6.61%) | 10 (3.97%) | ||
| Other | 14 (10.69%) | 11 (9.09%) | 25 (9.92%) | ||
| Lymph node metastasis, n (%) | |||||
| Yes | 92 (70.23%) | 48 (39.67%) | 140 (55.56%) | 23.791 | 0.000 |
| No | 39 (29.77%) | 73 (60.33%) | 112 (44.44%) | ||
| TNM staging, n (%) | |||||
| I + II | 25 (19.08%) | 66 (54.55%) | 91 (36.11%) | 34.285 | 0.000 |
| III | 106 (80.92%) | 55 (45.45%) | 161 (63.89%) | ||
| Molecular subtype, n (%) | |||||
| HER-2 | 13 (9.92%) | 14 (11.57%) | 27 (10.71%) | 2.017 | 0.569 |
| Luminal A | 36 (27.48%) | 33 (27.27%) | 69 (27.38%) | ||
| Luminal B | 41 (31.30%) | 45 (37.19%) | 86 (34.13%) | ||
| TNBC | 41 (31.30%) | 29 (23.97%) | 70 (27.78%) | ||
| Histologic grade, n (%) | |||||
| I | 6 (4.58%) | 19 (15.7%) | 25 (9.92%) | 22.983 | 0.000 |
| II | 53 (40.46%) | 69 (57.02%) | 122 (48.41%) | ||
| III | 72 (54.96%) | 33 (27.27%) | 105 (41.67%) | ||
| Sites of recurrence and metastasis, n (%) | |||||
| Bone | 57 (43.51%) | – | – | ||
| Lung | 42 (32.06%) | – | – | ||
| Liver | 31 (23.66%) | – | – | ||
| Brain | 23 (17.56%) | – | – | ||
| Chest wall (recurrence) | 17 (12.98%) | – | – | ||
| Other | 18 (13.74%) | – | – | ||
| Number of sites, n (%) | |||||
| Single | 91 (69.47%) | – | – | ||
| Multiple | 40 (30.53%) | – | – | ||
Other metastatic sites refer to pleural metastasis, peritoneal metastasis, and adrenal metastasis.
Number of sites indicates the number of sites with recurrence and/or metastasis. Thereinto, patients with recurrence and metastasis also belong to “multiple.” TNM, tumor node metastasis; TNBC, triple-negative breast cancer.